References
- Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. Br J Psychiatry 2002; 180: 104–9
- Katon W, Von Korff M, Lin E, Simon G, Walker E, Unutzer J, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: A randomised trial. Arch Gen Psych 1999; 56: 1109–15
- Atherton-Naji A, Hamilton R, Riddle W, Naji S. Improving adherence to antidepressant drug treatment in primary care: A feasibility study for a randomised controlled trail of educational intervention. Prim Care Psychiatry 2001; 2: 61–7
- Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psyhiatry 2002; 63: 331–6
- Lepola U, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–17
- Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102
- Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomised, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131–7
- Rush AJ, Bose A. Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21: 26–32
- Koponen H, Lepola U. Psychiatric drug trials and placebo. Nord J Psychiatry 2005; 59: 233–7
- Al-Windi A. Depression in general practice. Nord J Psychiatry 2005; 59: 272–7
- Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry 2002; 159: 469–73
- Posternak MA, Zimmerman M, Keitner GI, Miller IW. A re-evaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002; 159: 191–200
- World Medical Association Declaration of Helsinki, October 2000, Edinburgh.
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psych 1979; 134: 382–9
- Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP. A comparison of depression rating scales. Br J Psych 1982; 141: 45–9
- Clinical Global Impression Scale (CGI). In: Guy W, editor. ECDEU. Assessment manual for Psychopharmacology Revised 1976;217–22.
- Lipman RS. Depression scales derived from the Hopkins Symptom Checklist. Assessment of depression, N Sartorius, TA Ban. Springer, Berlin 1986; 232–48
- Taragano F, Lyketsos CG, Paz J, Schapira M, Comesana Diaz E, Klimovsky S. An open-label trial of sertraline for the treatment of major depression in primary care. Ann Clin Psychiatry 1999; 11: 67–71
- Devanand DP. An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. J Geriatr Psychiatry Neurol 2004; 17: 219–24
- Rasmussen NA, SchrØder P, Olsen LR, BrØsgaard M, Undén M, Bech P. Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nord J Psychiatry 2005; 59: 173–8
- Trivendi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice Am. J. Psychiatry 2006; 163: 28–40
- Work group on major depressive disorder. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150: No 4 ( Suppl).
- Meyers ED, Calvert EJ. Information, compliance and side-effects: A study of patients on antidepressant medication. Br J Clin Pharmacol 1984; 17: 21–5